One ‐year clinical experience on the use of Nintedanib in systemic sclerosis
We reviewed eleven patients with Systemic Sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and who started Nintedanib. AbstractWe reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Luca Magnani,
Amelia Spinella,
Sofia Testoni,
Federica Lumetti,
Chiara Scelfo,
Lucia Dardani,
Gianluigi Bajocchi,
Enrico Clini,
Carlo Salvarani,
Dilia Giuggioli Tags: CASE SERIES Source Type: research
More News: Corticosteroid Therapy | Diarrhoea | Pneumonia | Prednisone | Respiratory Medicine | Rituxan | Scleroderma | Smokers | UK Health